red spots; full body rash; developed severe edema; My skin began to sluff off / My skin is still shedding daily; onset of Pityriasis Rubra Pilaris; joint issues with pain; joint issues with pain; skin on my feet and hands are extremely thick and painful; skin on my feet and hands are extremely thick and painful; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 54 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 31Mar2021 14:00 (Lot number: ER8737) at the age of 54 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Disabled due to spine" (unspecified if ongoing); "Panic disorder" (unspecified if ongoing); "Known allergy-Latex" (unspecified if ongoing). Concomitant medication(s) included: GABAPENTIN; ABILIFY; CLONAZEPAM. Past drug history included: Known allergy-cortazone shot, reaction(s): "Drug allergy". Vaccination history included: Pfizer (DOSE 1, SINGLE, Batch/Lot No: EN6199, Location of injection: Arm Left), administration date: 10Mar2021, when the patient was 54 years old, for Covid-19 immunization. The following information was reported: RASH MACULAR (hospitalization, disability) with onset 01Apr2021, outcome "not recovered", described as "red spots"; RASH (hospitalization, disability) with onset 01Apr2021, outcome "not recovered", described as "full body rash"; OEDEMA (hospitalization, disability) with onset 01Apr2021, outcome "not recovered", described as "developed severe edema"; SKIN EXFOLIATION (hospitalization, disability) with onset 01Apr2021, outcome "not recovered", described as "My skin began to sluff off / My skin is still shedding daily"; PITYRIASIS RUBRA PILARIS (hospitalization, disability) with onset 01Apr2021, outcome "not recovered", described as "onset of Pityriasis Rubra Pilaris"; ARTHROPATHY (hospitalization, disability), ARTHRALGIA (hospitalization, disability) all with onset 01Apr2021, outcome "not recovered" and all described as "joint issues with pain"; SKIN HYPERTROPHY (hospitalization, disability), PAIN OF SKIN (hospitalization, disability) all with onset 01Apr2021, outcome "not recovered" and all described as "skin on my feet and hands are extremely thick and painful". The patient was hospitalized for rash macular, rash, oedema, skin exfoliation, pityriasis rubra pilaris, arthropathy, arthralgia, skin hypertrophy, pain of skin (hospitalization duration: 12 day(s)). The events "red spots", "full body rash", "developed severe edema", "my skin began to sluff off / my skin is still shedding daily", "onset of pityriasis rubra pilaris", "joint issues with pain", "joint issues with pain", "skin on my feet and hands are extremely thick and painful" and "skin on my feet and hands are extremely thick and painful" were evaluated at the physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: sars-cov-2 antibody test: (25Jun2021) negative, notes: Nasal Swab. Therapeutic measures were taken as a result of rash macular, rash, oedema, skin exfoliation, pityriasis rubra pilaris, arthropathy, arthralgia, skin hypertrophy, pain of skin. Treatment included IV fluids, wrapped legs for edema, biopsies. Clinical course: Within 24 hours of second shot, the patient had red spots on chest, arms, legs, which changed into a full body rash. Her skin began to sluff off. She developed severe edema. She was hospitalized, and had 3 biopsies, which revealed the onset of Pityriasis Rubra Pilaris. She still have it today, without much relief to from her scalp to the soles of her feet. She has joint issues with pain, and the skin on her feet and hands are extremely thick and painful. Her skin was still shedding daily. The biggest problem with her insurance Medicare, was that they will not pay for many of the treatment options, because these are dermatological treatments. She was currently seeing her primary care doctor and dermatologist. The patient had no other vaccine in four weeks, no prior vaccination.